/PRNewswire/ The "Head and Neck Squamous Cell Carcinomas (HNSCC) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor.
- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo- Future studies will also involve assessments of the B7H3.
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022